255 related articles for article (PubMed ID: 34527346)
1. The efficacy and safety of immunotherapy in thymic epithelial tumors: more effective, more risky: a systematic review.
Song X; Fan J; Zhu L; Wang Z; He Y; Zhou C
J Thorac Dis; 2021 Aug; 13(8):5093-5103. PubMed ID: 34527346
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives.
Ao YQ; Gao J; Wang S; Jiang JH; Deng J; Wang HK; Xu B; Ding JY
Mol Cancer; 2023 Apr; 22(1):70. PubMed ID: 37055838
[TBL] [Abstract][Full Text] [Related]
3. Fatal toxicity induced by anti-PD-1 immune checkpoint inhibitor in thymic epithelial tumor.
Jing X; Zhu H; Li Y; Jia W; Zhai X; Li J; Yu J
Immunotherapy; 2022 Oct; 14(14):1097-1107. PubMed ID: 36093721
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for thymoma.
Jakopovic M; Bitar L; Seiwerth F; Marusic A; Krpina K; Samarzija M
J Thorac Dis; 2020 Dec; 12(12):7635-7641. PubMed ID: 33447455
[TBL] [Abstract][Full Text] [Related]
5. Thymic tumors and immune checkpoint inhibitors.
Yokoyama S; Miyoshi H
J Thorac Dis; 2018 May; 10(Suppl 13):S1509-S1515. PubMed ID: 29951302
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors.
Song JS; Kim D; Kwon JH; Kim HR; Choi CM; Jang SJ
Front Oncol; 2019; 9():1055. PubMed ID: 31681591
[No Abstract] [Full Text] [Related]
7. Evolving treatment landscape in thymic epithelial tumors: From mechanism to therapy.
Yang Y; Yu Y; Fan Y; Li H
Biochim Biophys Acta Rev Cancer; 2024 Jun; ():189145. PubMed ID: 38942215
[TBL] [Abstract][Full Text] [Related]
8. Understanding the landscape of immunotherapy in thymic epithelial tumors.
Maniar R; Loehrer PJ
Cancer; 2023 Apr; 129(8):1162-1172. PubMed ID: 36808725
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of immune checkpoint inhibitors (ICIs) combined with antiangiogenic therapy for thymic epithelial tumors (TETs): a retrospective study.
Xiang J; Si J; Hao Y; Wei J; Wang W; Guan Y; Xu C; Song Z
Transl Cancer Res; 2023 Mar; 12(3):550-557. PubMed ID: 37033336
[TBL] [Abstract][Full Text] [Related]
10. Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: A multicentre retrospective study.
Wang W; Lin G; Hao Y; Guan Y; Zhang Y; Xu C; Wang Q; Wang D; Jiang Z; Cai J; Lou G; Song Z; Zhang Y
Eur J Cancer; 2022 Oct; 174():21-30. PubMed ID: 35970032
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitors for treatment of thymic epithelial tumors: how to maximize benefit and optimize risk?
Zhao C; Rajan A
Mediastinum; 2019 Sep; 3():. PubMed ID: 31608320
[TBL] [Abstract][Full Text] [Related]
12. Brief Report: High Levels of CD47 Expression in Thymic Epithelial Tumors.
Sun TY; Nguyen B; Chen SB; Natkunam Y; Padda S; van de Rijn M; West R; Neal JW; Wakelee H; Riess JW
JTO Clin Res Rep; 2023 Apr; 4(4):100498. PubMed ID: 37020927
[TBL] [Abstract][Full Text] [Related]
13. Programmed Death-ligand 1 (PD-L1) Expression in Thymic Epithelial Tumors.
Bedekovics J; Beke L; Mokanszki A; Szilagyi S; Mehes G
Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):1-9. PubMed ID: 30499814
[TBL] [Abstract][Full Text] [Related]
14. Narrative review of immunotherapy in thymic malignancies.
Benitez JC; Besse B
Transl Lung Cancer Res; 2021 Jun; 10(6):3001-3013. PubMed ID: 34295693
[TBL] [Abstract][Full Text] [Related]
15. Immunobiology of Thymic Epithelial Tumors: Implications for Immunotherapy with Immune Checkpoint Inhibitors.
Tateo V; Manuzzi L; De Giglio A; Parisi C; Lamberti G; Campana D; Pantaleo MA
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33260538
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitor myocarditis in thymic epithelial tumors: a case report and literature review.
Feng Y; Zheng P; Zhang W; Yang S; You Y; Chen Y; Ye Y
Transl Cancer Res; 2024 Feb; 13(2):1208-1218. PubMed ID: 38482422
[TBL] [Abstract][Full Text] [Related]
17. Immunologic Significance of CD80/CD86 or Major Histocompatibility Complex-II Expression in Thymic Epithelial Tumors.
Ikeda H; Nagasaki J; Shimizu D; Katsuya Y; Horinouchi H; Hosomi Y; Tanji E; Iwata T; Itami M; Kawazu M; Ohe Y; Suzuki T; Togashi Y
JTO Clin Res Rep; 2023 Oct; 4(10):100573. PubMed ID: 37799325
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for Management of Thymic Epithelial Tumors: A Double-Edged Sword.
Ballman M; Zhao C; McAdams MJ; Rajan A
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565190
[TBL] [Abstract][Full Text] [Related]
19. Programmed death-ligand 1 expression profiling in thymic epithelial cell tumors: Clinicopathological features and quantitative digital image analyses.
Ishihara S; Okada S; Ogi H; Kodama Y; Shimomura M; Tsunezuka H; Itoh K; Marx A; Inoue M
Lung Cancer; 2020 Jul; 145():40-47. PubMed ID: 32402921
[TBL] [Abstract][Full Text] [Related]
20. Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.
Arbour KC; Naidoo J; Steele KE; Ni A; Moreira AL; Rekhtman N; Robbins PB; Karakunnel J; Rimner A; Huang J; Riely GJ; Hellmann MD
PLoS One; 2017; 12(8):e0182665. PubMed ID: 28771603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
